Skip to search formSkip to main contentSkip to account menu

ivacaftor 125 MG / lumacaftor 200 MG Oral Tablet [ORKAMBI]

Known as: ORKAMBI (lumacaftor 200 MG / ivacaftor 125 MG) Oral Tablet, ORKAMBI 200 MG / 125 MG Oral Tablet, lumacaftor 200 mg / ivacaftor 125 mg ORAL TABLET, FILM COATED [ORKAMBI] 
National Institutes of Health

Related topics

Related topics

21 relations
AmmoniaBrilliant blue FCFCroscarmellose SodiumHYPROMELLOSE ACETATE SUCCINATE 06081224 (3 MM2-S)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Anti-Infectives Restore ORKAMBI® Rescue of F508del-CFTR Function in Human Bronchial Epithelial Cells Infected with Clinical Strains of P. aeruginosa
Chronic infection and inflammation are the primary causes of declining lung function in Cystic Fibrosis (CF) patients. ORKAMBI… 
2020
2020
Treatment of Cystic Fibrosis Patients Homozygous for F508del with Lumacaftor-Ivacaftor (Orkambi®) Restores Defective CFTR Channel Function in Circulating Mononuclear Cells
The treatment of cystic fibrosis (CF) patients homozygous for the F508del mutation with Orkambi®, a combination of a corrector… 
2019
2019
ORKAMBI-Mediated Rescue of Mucociliary Clearance in Cystic Fibrosis Primary Respiratory Cultures Is Enhanced by Arginine Uptake, Arginase Inhibition, and Promotion of Nitric Oxide Signaling to the…
ORKAMBI, a combination of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective processing… 
2019
2019
Activity of lumacaftor is not conserved in zebrafish Cftr bearing the major cystic fibrosis‐causing mutation
F508del‐cystic fibrosis transmembrane conductance regulator (CFTR) is the major mutant responsible for cystic fibrosis (CF… 
Review
2018
Review
2018
Triplet CFTR modulators: future prospects for treatment of cystic fibrosis
Cystic fibrosis (CF) is an autosomal recessive genetic disease characterized by mutations in the cystic fibrosis transmembrane… 
2018
2018
IPD2.12 Treatment with Orkambi™ in Phe508del homozygous CF patients is associated with improvement in cognition
Review
2017
Review
2017
CFTR-NHERF2-LPA2 Complex in the Airway and Gut Epithelia
The cystic fibrosis transmembrane conductance regulator (CFTR) is a cAMP- and cGMP-regulated chloride (Cl−) and bicarbonate (HCO3… 
2017
2017
ORKAMBI®, Zystische Fibrose (CF, Mukoviszidose) | STO
Fachkommunikation (Sales Folder, DDI Facher) Patientenkommunikation (Therapiestart, Ernahrungshinweise) Patientenkommunikation… 
2017
2017
WS12.2 Nurse-led algorithm for monitoring of CF patients with end-stage lung disease on Orkambi® treatment – preliminary results
Review
2016
Review
2016
Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis
Lumacaftor/ivacaftor (Orkambi™) is a fixed-dose tablet containing a corrector (lumacaftor) and potentiator (ivacaftor) of the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)